Skip to content

Depression: all studies

Page 795 of 1,034: studies 7,941 to 7,950 of 10,336, newest first. Back to the depression overview

Research

Proteomic changes induced by harmine in human brain organoids reveal signaling pathways related to neuroprotection

bioRxiv (Cold Spring Harbor Laboratory) June 17, 2021 Karina Karmirian, Livia Goto-Silva, Juliana Nascimento et al. 1 citation preprint

Abstract Harmine is a β-carboline found in Banisteriopsis caapi , a constituent of ayahuasca brew. Ayahuasca is consumed as a beverage in native Americans’ sacred rituals and in religious ceremonies in Brazil. Throughout the years, the beneficial effects of ayahuasca to improve mental health and life quality have been reported, which propelled the investigation of its therapeutic potential to...

Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study

JMIR Research Protocols June 16, 2021 H. Mansell, D. Quinn, L. Kelly et al.

Background Despite the lack of evidence on the use of cannabis for the treatment of attention-deficit/hyperactivity disorder (ADHD), the growing perception that cannabis is safe has led more patients and caregivers to self-medicate. Some psychiatrists now authorize medicinal cannabis for patients with ADHD with features of oppositional defiant disorder (ODD) to curtail the unregulated (ie,...

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Irish Journal of Medical Science June 15, 2021 Kate Corrigan, Maeve Haran, Conor Mccandliss et al. 79 citations

Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods A questionnaire capturing demographics, diagnoses, previous psychedelic and...

Natural and Experimental Evidence Drives Marmosets for Research on Psychiatric Disorders Related to Stress

Frontiers in Behavioral Neuroscience June 11, 2021 Maria Bernardete Cordeiro de Sousa, Maria Lara Porpino de Meiroz Grilo, Nicole Leite Galvão‐coelho 7 citations

Knowledge of the behavioral ecology of marmosets carried out in their natural habitat associated with the advent of a non-invasive technique for measuring steroid hormones in feces has made a significant contribution to understanding their social relationships and sexual strategies. These studies showed that they are mainly monogamous, live in relatively stable social groups according to a...

DOI: 10.3389/fnbeh.2021.674256 (opens in new tab) Behavioral syndrome Context archaeology Developmental psychology Marmoset +7

Mindfulness y educación física en la población universitaria. Una revisión sistemática (Mindfulness and physical education in University population. A systematic review)

Retos June 10, 2021 Irene López Secanell, Javier Gené‐Morales, Nerea Hernaiz Agreda 4 citations

El objetivo de este estudio fue revisar las conclusiones de los artículos publicados en los últimos seis años sobre el uso del mindfulness en la población universitaria. Además, se examinaron cuántos de estos estudios se aplican dentro del campo de la Educación Física Universitaria. Se analizaron los artículos publicados desde 2014 hasta 2020 mediante las bases de datos ERIC, Taylor and...

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Frontiers in Psychiatry June 9, 2021 Simon Ruffell, Nige Netzband, WaiFung Tsang et al. 74 citations

Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took...

DOI: 10.3389/fpsyt.2021.687615 (opens in new tab) Ayahuasca Anxiety Mental health Beck depression inventory +3

Psilocybin: A brief overview for psychiatric mental health nurse practitioners

Perspectives In Psychiatric Care June 8, 2021 Dina Fradkin 3 citations

The use of psychedelics, such as psilocybin, has emerged in recent literature as a novel therapeutic treatment for various psychiatric disorders, including substance use, depression, and anxiety. While international and domestic trials are currently underway, there is data demonstrating both the relative safety and potential efficacy of psilocybin. Psychiatric mental health nurse practitioners...

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Experimental and Clinical Psychopharmacology June 7, 2021 Colleen Fogg, Timothy I. Michaels, Sara de la Salle et al. 53 citations

Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress...

DOI: 10.1037/pha0000490 (opens in new tab) Psychotherapist Clinical psychology

Adjunct pharmacotherapy for psychotherapy

BJPsych Open June 1, 2021 Jessica Lochtenberg, Ari P. Kirshenbaum, Matthew Johnson

Aims: A variety of pharmacotherapies have been used to assist the psychotherapy process as “adjunctive therapies.” These drugs are used in an acute, targeted fashion, such that they are explicitly delivered in the context of psychotherapy for anxiety, mood and substance-dependence disorders (SUDs). Our narrative review highlights the potential of medically-assisted psychotherapy by outlining...

Brief Mindfulness Intervention vs. Health Enhancement Program for Patients Undergoing Dialysis: A Randomized Controlled Trial

Healthcare June 1, 2021 Marouane Nassim, Haley Park, Elena Dikaios et al. 20 citations

BACKGROUND: Between 20-50% of patients undergoing maintenance dialysis for end-stage kidney disease experience symptoms of depression and/or anxiety, associated with increased mortality, greater health care utilization, and decreased quality of life. It is unknown whether mindfulness-based interventions can improve depression and anxiety symptoms in patients receiving this treatment. METHODS:...